A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
Status:
Withdrawn
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy and safety of MK-4827 in participants with relapsed
mantle cell lymphoma (MCL) and in a subset of participants with inactivation of the
Ataxia-Telangiectasia Mutated (ATM) gene.